Olomoucine (high purity) | Enzo Life Sciences ALX-350-013-M005 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Enzo Life Sciences

other brands :

Stressgen, BioMol, Alexis Corporation, Assay Designs, Alexis

product type :

chemical

product name :

Olomoucine (high purity)

catalog :

ALX-350-013-M005

quantity :

5 mg

citations: 7

Reference
Monaco E, Beaman Hall C, Mathur A, Vallano M. Roscovitine, olomoucine, purvalanol: inducers of apoptosis in maturing cerebellar granule neurons. Biochem Pharmacol. 2004;67:1947-64 pubmed
Alessi F, Quarta S, Savio M, Riva F, Rossi L, Stivala L, et al. The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity. Exp Cell Res. 1998;245:8-18 pubmed
Meijer L, Kim S. Chemical inhibitors of cyclin-dependent kinases. Methods Enzymol. 1997;283:113-28 pubmed
Havlicek L, Hanus J, Vesely J, Leclerc S, Meijer L, Shaw G, et al. Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. J Med Chem. 1997;40:408-12 pubmed
Vesely J, Havlicek L, Strnad M, Blow J, Donella Deana A, Pinna L, et al. Inhibition of cyclin-dependent kinases by purine analogues. Eur J Biochem. 1994;224:771-86 pubmed
Misteli T, Warren G. Mitotic disassembly of the Golgi apparatus in vivo. J Cell Sci. 1995;108 ( Pt 7):2715-27 pubmed
Abraham R, Acquarone M, Andersen A, Asensi A, Belle R, Berger F, et al. Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases. Biol Cell. 1995;83:105-20 pubmed

product information

Product ID :

ALX-350-013

Catalog Number :

ALX-350-013-M005

Product Name :

Olomoucine (high purity)

Product Type :

Biochemical

Size :

5 mg

list of Pubmed id :

15130771, 9828096, 9251015, 9046330, 7925396, 7593312, 7549905

Product Description :

Olomoucine is a purine derivative which acts as a potent and selective inhibitor of CDK1 (p34cdc2)/cyclin B and related kinases. It acts by competing for the ATP binding domain of the kinase. Of 35 protein kinases tested, olomoucine inhibited p33CDK2/cyclin A, p33CDK2/cyclin E, p34cdc2/cyclin B, p33CDK5/p35 and erk1 with IC50 of 7, 7, 7, 3 and 25µM respectively. The related kinases p34CDK4/cyclin D and p40CDK6/cyclin D3 were not inhibited or were less sensitive to olomoucine, IC50 > 1000 and 250µM respectively. PKC, PKA, PKG, CaM kinase II, MLC kinase, CK2, EGFR tyrosine kinase, p56lck, p56lyn, p60c-src, v-abl and insulin receptor tyrosine kinase are not inhibited or are weakly inhibited at 1mM. It delays mouse oocyte maturation and inhibits the growth of a variety of human cell lines including Rhabdomyosarcoma cell line Rh1, Rh18, Rh28 and Rh30; MCF-7, KB-3-1 and their adriamycin-resistant counterparts (IC50=18-86µM). It inhibits DNA synthesis in interleukin-2-stimulated T lymphocytes and triggers a G1 arrest similar to interleukin-2 deprivation. Can be used to synchronize cells in G1. Triggers apoptosis in target tumor cells in vitro and in vivo and in maturing cerebellar granule neurons. N9-Isopropyl-olomoucine and the negative control Iso-olomoucine are also available.

ALTnames :

6-Benzylamino-2-(2-hydroxyethylamino)-9-methylpurine

Purity :

≥98%

Storage :

-20°C